Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Xenogen (XGEN) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (10)	4/12/2005 1:44:46 PM
From: tuck	Read Replies (1) \| Respond to of 45

>>ALAMEDA, Calif., April 12 /PRNewswire-FirstCall/ -- Xenogen Corporation (Nasdaq: XGEN - News) announced today a partnership with MIR Preclinical Services (MIR), a contract research organization, for the purchase and sublicense of Xenogen's biophotonic imaging, or real-time in vivo imaging, technologies. MIR is now authorized to use Xenogen's proprietary technology to conduct pre- clinical research for pharmaceutical and biotech companies, across a variety of therapeutic areas excluding infectious diseases. Under this first-of-its-kind agreement with a contract research organization, MIR is purchasing one of Xenogen's biophotonic imaging systems (IVIS® Imaging System) and licensing its patented methods of biophotonic imaging. The partnership will expand the availability of Xenogen's technology into pre-clinical drug development as a service, and provide a broader range of companies with access to its biophotonic imaging technology. "Xenogen's technology augments our portfolio of preclinical imaging systems and solutions and helps us maintain a leadership position in the field of Molecular Imaging," said Wilbur Leopold, Ph.D., president, MIR Preclinical Services. "This unique non-invasive imaging technology essentially lights up biological processes in animals, enabling us to identify and follow diseases and drug function at the molecular level in vivo. The addition of Xenogen technology will enhance our efforts to provide our clients with integrated and simultaneous assessment of efficacy and mechanism of action (pharmacodynamics), speeding the drug discovery process." Xenogen's biophotonic technologies enable researchers -- for the first time -- to visualize and track biological processes in living animals, non- invasively and in real time, including analysis of gene function, the spread of disease and the effects of a drug candidate throughout the system. With it, researchers can better understand the mechanisms of action of diseases and drugs. "Biophotonic imaging technology is quickly becoming the new research standard in drug development, illustrated by its adoption by leading biotech and pharmaceutical companies," said Pamela R. Contag, Ph.D., president of Xenogen Corporation. "Dr. Leopold's expertise in cancer drug discovery and development that he gained with Parke-Davis and Pfizer prior to becoming the president of MIR adds a new dimension to Xenogen's product offerings." Xenogen holds exclusive patent rights to the essential methods for real- time in vivo biophotonic imaging. The company incorporates into microorganisms, cells and living animals the bioluminescent gene that makes a firefly glow, which it uses as a biological tag to see what's happening inside the animal (imaged with its IVIS Imaging System).<< snip Plenty willing to trumpet to the world that they sold a system, and that they hold exclusive patent rights for real- time in vivo biophotonic imaging. If you want to know those rights are being challenged? You've got to dig in EDGAR. I've learned the hard way about investing in companies with promising products and "promising" management. Still no position, but obviously, still watching pretty closely. Cheers, Tuck